Comparison of US-guided Single-dose Thoracic Paravertebral, Erector Spinae Plane and Serratus Anterior Plane Blocks

Sponsor
Istanbul University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05431062
Collaborator
(none)
60
3
9

Study Details

Study Description

Brief Summary

This study evaluates the analgesic effects of ultrasound-guided regional techniques, Thoracic Paravertebral Block (TPVB), Erector Spinae Plane Block (ESPB) and Serratus Anterior Plane Block(SAPB) by comparing postoperative total morphine consumption, first analgesic requirement time, and postoperative pain scores ( FLACC/NRS), postoperative chronic pain in 3rd month in pediatric patients undergoing thoracic surgery. The investigators also aim to observe the side effects of these techniques such as nausea, vomiting, bradycardia, hypotension, respiratory depression

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

Thoracic surgery is one of the most common causes of postoperative severe pain due to the damage to intercostal nerves, irritation of the pleura and rib retraction. Effective analgesia provides patient comfort and enables early mobilization, reducing complications such as pneumonia, respiratory failure, hypoxia, and hypercapnia. In pediatric patients, nonsteroid anti-inflammatory drugs, opioids and regional analgesia techniques can be used for multimodal analgesia. Several side effects of opiates such as respiratory depression, nausea, vomiting, itching, addiction, and sedation effect patients' comfort and delay discharge. Nowadays US-guided truncal block techniques such as thoracic paravertebral block (TPVB) become popular. TPVB provide the somatosensorial and visceral block with an injection of the local anaesthetic agent into the paravertebral space. Existing evidence demonstrates the non inferiority of TPVB compared with TEA for postoperative analgesia and TPVB can reduce side effects. Erector Spina Plan Block (ESPB) was first described in 2016 as an ultrasound-guided truncal block for thoracic neuropathic pain and now ESPB uses for many different thoracics and abdominal surgeries for postoperative analgesia. Several studies have shown that ESPB can provide adequate analgesia in postoperative thoracic pain. ESPB is gaining popularity because its application is easy and safe compared with TPVB. Another new US-guided regional anaesthetic block technique, the serratus anterior plane block (SAPB), targets the plane above or below the serratus anterior muscle in the midaxillary line and provides analgesia to a hemithorax by blocking the lateral branches of the intercostal nerves, thoracicus longus and thoracodorsal nerves. The SAP block provides analgesia to the 2nd and 9th thoracic dermatomes. The SAP block is safe, and easy to perform, owing to its easy-to-learn technique and distinct bony landmarks. So, it can be an attractive alternative for pain relief after thoracic surgery.

In this study, Investigators aim to compare the efficacy of these three techniques in pediatric patients. The primary hypothesis is the analgesic efficacy of SAPB will be equivalent to TPVB and RSPB. The primer outcome is postoperative total narcotic analgesic consumption in 24 hours. The seconder outcomes are; time of postoperative first analgesic requirement, postoperative pain scores (FLACC - NRS) in 0.-15.-30.-45.minutes and 1.-2.-6.-12.-24.-48. hours, chronic thoracic pain 3 months after surgery, intraoperative additional fentanyl requirement, postoperative additional paracetamol requirement, intraoperative hemodynamic parameters, first mobilization time, side effects, technical complications, and the satisfaction of patient-surgeon.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Prospective Observational StudyProspective Observational Study
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Screening
Official Title:
Comparison of US-guided Single-dose Thoracic Paravertebral Block, Erector Spinae Plane Block and Serratus Anterior Plane Block in Pediatric Patients Undergoing Thoracic Surgery.
Anticipated Study Start Date :
Jul 1, 2022
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
Apr 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Thoracic paravertebral block

USG guided TPVB will be performed with 0.5 mL/kg %0.25 Buvicaine in the paravertebral space.

Drug: Bupivacain
%0.25
Other Names:
  • Marcaine
  • Active Comparator: Erector spinae plane block

    USG guided ESPB will be performed with 0.5 mL/kg %0.25 Buvicaine into the facial plane between erector spine muscle and transverse process

    Drug: Bupivacain
    %0.25
    Other Names:
  • Marcaine
  • Active Comparator: Serratus anterior plane block

    USG guided ESPB will be performed with 0.5 mL/kg %0.25 Buvicaine into the facial plane between serratus anterior muscle and external intercostal muscles

    Drug: Bupivacain
    %0.25
    Other Names:
  • Marcaine
  • Outcome Measures

    Primary Outcome Measures

    1. Postoperative Iv Morphine Consumption [Up to 24 hours]

      The total dosage of iv morphine consumption in 24 hours.

    Secondary Outcome Measures

    1. Face, Legs Avtivity, Cry, Consolability (FLACC) scores [Up to 48 hours]

      It corporates five categories of behavior, each scored on 0-2 point scale so that total score ranges from 0 to 10. Total scores of 0-3 is defined as mild or no pain, 4-7 as moderate, and 8-10 as severe pain

    2. Postoperative NRS Score (Numeric Rating Scale) [Up to 48 hours]

      A numerical rating scale (NRS) requires the patient to rate their pain on a defined scale. For example, 0-10 where 0 is no pain and 10 is the worst pain imaginable

    3. Time of Postoperative First Analgesic Requirement Time [Up to 48 hours]

      Time of postoperative first analgesic requirement time.

    4. Additional IV Paracetamol Dosage In The Postoperative Period [Up to 48 hours]

      15mg/kg iv paracetamol will be administered 30 minutes before extubation. In the postoperative follow-up that will be performed every 6 hours,15mg/kg iv paracetamol will be administered if the FLACC score is >3 or the NRS score is >4.

    5. Intraoperative Heart Rate (beat/min) [Intraoperative Period]

      To be measured through the operation at intervals of 5 minutes

    6. Intraoperative Mean Arterial Pressure(MAP)(mmHg) [Up to end of the operation]

      To be measured through the operation at intervals of 5 minutes

    7. Number of patients who need intraoperative additional Fentanyl [Up to end of the operation]

      Intraoperative Additional Fentanyl Requirement

    8. Chronic Thoracic Pain [Up to 3 months]

      Presence of thoracic pain due to the incision after 3 months of the thoracic surgery.

    9. Length of Hospital Stay [Up to first week]

      Length of Hospital Stay

    Other Outcome Measures

    1. Incidence of PONV (postoperative nausea and vomiting) [Up to 48 hours]

      Incidence of postoperative nausea and vomiting.

    2. Respiratuar Depression [Up to 48 hours]

      Incidence of respiratory depression due to ıv morphine in the postoperative follow-up.

    3. Postoperative sedation scale [Up to 48 hours]

      A numerical rating sedation scale requires the patient to rate their sedation on a defined scale. For example, 1: deeply asleep, 2: lightly asleep, 3: drowsy, 4: fully awake and alert

    4. Itching [Up to 48 hours]

      Incidence of itching due to iv morphine in the postoperative follow-up.

    5. Incidence of Complications Due To The Regional Block [Up to first week]

      Incidence of dural puncture,pneumothorax,infection,neural damage.

    6. First Mobilization Time [Up to 48 hours]

      First mobilization time .

    7. Need of Intensive Care Unit Follow-Up [Up to 48 hours]

      The number of patients who need ICU follow-up.

    8. Family Satisfaction [Up to 48 hours]

      Satisfaction score; 0: very unsatisfied 3:very unsatisfied

    9. Surgeon Satisfaction [Up to 48 hours]

      Satisfaction score; 0: very unsatisfied 3:very unsatisfied

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    1 Year to 14 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    1-14 age patients undergoing thoracic surgery, ASA 1-2-3, Patients without chronic opioid use

    Exclusion Criteria:

    Denial of patient or parents, Infection of the local anaesthetic area, Infection of the central nervous system, Coagulopathy, Brain tumours, Known allergy against local anaesthetics.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Istanbul University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Meltem Savran Karadeniz, associated professor, Istanbul University
    ClinicalTrials.gov Identifier:
    NCT05431062
    Other Study ID Numbers:
    • 2021/808
    First Posted:
    Jun 24, 2022
    Last Update Posted:
    Jun 24, 2022
    Last Verified:
    Jun 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Meltem Savran Karadeniz, associated professor, Istanbul University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 24, 2022